Immune Therapy Holdings

Immune Therapy Holdings AB or ITH is a Swedish biotechnology R&D holding company headquartered at the Karolinska Institutet and Karolinska University Hospital in Stockholm.

Immune Therapy Holdings AB
Company typePrivately held Aktiebolag
IndustryResearch and development
Founded2005
HeadquartersStockholm, Sweden
Key people
Ahsan Amjad (CEO), Ola Winqvist (CTO), Hans Glise (Chairman),
ProductsImmunotherapy
Websiteithgroup.se

ITH's research is primarily focused on its Tailored Leukapheresis (TLA) treatment for immune mediated inflammatory diseases (IMIDs).[1]

Tailored Leukapheresis treatment

edit

Tailored Leukapheresis (TLA) treatment is an apheresis immunotherapy for selective removal of disease-causing pro-inflammatory cells extracorporeally, which has therapeutic application in various IMIDs that are caused and maintained by inflammation.

TLA utilises the natural affinity of chemokines and chemokine receptors to selectively attract, bind, and deplete circulating pro-inflammatory cells en route to the site of inflammation. It is the first[citation needed], and hitherto novel, apheresis technology with a demonstrated efficacy in targeting and removing selected leukocytes while leaving all other blood cells unaffected.[2]

The immunotherapy has been evaluated in a Phase I/II placebo-controlled clinical trial, where all primary and secondary clinical endpoints were met and the treatment showed an absence of any side effects of clinical significance.[3]

Awards and funding

edit

TLA received the Dagens Medicin's Athena Prize (Sweden, 2013)[4] and Universal Biotech Innovation Prize (France, 2012).[5] During 2014, TLA was selected by the Swedish Institute for its Innovative Sweden exhibition that highlights Swedish innovativeness worldwide.[6]

TLA has received competitive research funding from the following sources:

Target market

edit

The global anti-inflammatory therapeutics market was $57.8 billion in 2010 and is estimated to increase at a CAGR of 5.8% between 2010 and 2017 to a total value of $85.9 billion.[10]

References

edit
  1. ^ ITH Introduction Archived 2014-03-23 at the Wayback Machine December 2012
  2. ^ Eberhardson, Michael; Marits, Per; Jones, Martina; Jones, Petra; Karlen, Per; Karlsson, Mats; Cotton, Graham; Woznica, Kerry; Maltman, Beatrice; Glise, Hans; Winqvist, Ola (2013). "Treatment of inflammatory bowel disease by chemokine receptor-targeted leukapheresis". Clinical Immunology. 149 (1): 73–82. doi:10.1016/j.clim.2013.05.021. PMID 23892544.
  3. ^ ClinicalTrials.Gov 2010
  4. ^ Dagens Medicin 2013
  5. ^ Universal Biotech 2012
  6. ^ Swedish Institute 2014
  7. ^ ITH VINNOVA Press Release 2010
  8. ^ EUROSTARS Project Archived 2014-03-23 at the Wayback Machine 2012
  9. ^ Swedish Medical Research Council December 2012
  10. ^ PR NewsWire Global Anti-Inflammatory Therapeutics Market 2011